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Some patients with antiphospholipid syndrome (APS) suffer pregnancy
morbidity (PM) but not vascular thrombosis (VT), whilst others suffer
VT only. Therefore, we compared the effects of IgG from VT+/PM and
VT/PM+ subjects on human first-trimester trophoblast (HTR8) cells.
Method of study
HTR-8 cells were incubated with APS VT+/PM, APS VT/PM+ or
healthy control (HC) IgG. We measured trophoblast invasion by cell
invasion assay; mRNA expression of TLR4 and adaptor proteins; phos-
phorylation of p38 MAPK, NFjB and ERK; and expression of interleu-
kin (IL)-8 and IL-6.
Results
VT/PM+ IgG, but not VT+/PM IgG significantly reduced HTR-8 inva-
sion. The effects on invasion were blocked by TLR-4 inhibition. Neither
VT+/PM nor VT/PM+ IgG altered MyD88 mRNA expression, phos-
phorylation of signalling molecules or cytokine expression.
Conclusions
VT/PM+ IgG exert functionally relevant effects on human trophoblast
cells but VT+/PM IgG do not.
Introduction
Patients with the antiphospholipid syndrome (APS)
have circulating antiphospholipid antibodies (aPL)
which cause vascular thrombosis (VT) and/or preg-
nancy morbidity (PM). APS is now recognized as the
most common cause of acquired hypercoagulability
in the general population1 and the most important
treatable cause of recurrent miscarriage.2 Despite
treatment with aspirin and heparin from early preg-
nancy, which significantly increases the live birth
rate in recurrent miscarriage patients with APS, the
incidence of severe late pregnancy complications
remains high3 and more targeted therapies are
required.
It was originally thought that pregnancy complica-
tions in patients with APS were due to thrombotic
events at the maternal–foetal interface. The success-
ful use of anticoagulants in preventing foetal loss in
these patients supported this notion. Histological
comparison, however, of products of conception from
aPL-positive and negative patients with recurrent
early miscarriage has shown a specific defect in
decidual endovascular trophoblast invasion in
patients with APS,4 whereas placental infarction is
not specific to patients with APS.5 Furthermore, aPL
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have been shown to have direct effects, both in vitro
and in vivo, on endometrial and trophoblast cells
resulting in impaired implantation and placental
development (reviewed in6). aPL that cause PM via
these non-thrombotic effects may not increase the
risk of VT, and conversely, aPL that cause VT may
not increase the risk of PM. This hypothesis fits with
clinical observations that some patients with APS and
VT never suffer PM (VT+/PM) and some patients
with APS and PM never suffer VT (VT/PM+) despite
many years of follow-up.7 It is therefore important to
compare the biological effects of IgG derived from
these patients with thrombotic and non-thrombotic
APS on cultured human cells in-vitro.
Lopez-Pedrera et al.8–10 have demonstrated that
monocytes isolated from patients with thrombotic
APS have different properties compared to monocytes
isolated from patients with non-thrombotic APS. In
patients with thrombotic APS only, they found
increased levels of circulating vascular endothelial
growth factor (VEGF) and its soluble receptor Flt-18
and increases in monocyte tissue factor (TF) expres-
sion, p38 mitogen-activated protein kinase (MAPK)
and nuclear factor kappa B (NFjB) activation and
protease activated receptor (PAR) 1 and 2 expres-
sion.10 Similar effects were seen in healthy volun-
teers’ monocytes exposed to pooled IgG from patients
with thrombotic APS. Supporting this observation, we
have shown that IgG isolated from individual patients
with thrombotic APS caused activation of p38 MAPK
and NFjB signalling pathways and up-regulation of
TF activity in human monocytes compared with IgG
from patients with non-thrombotic APS, which lacked
these effects.11 These effects were reduced in the pres-
ence of toll-like receptor (TLR)4 inhibitors.
In contrast, very few studies have compared the
effects of thrombotic versus non-thrombotic APS-IgG
in cell types relevant to PM such as trophoblast and
endometrium. Mulla et al.12 showed that two murine
monoclonal anti-b2 glycoprotein I (b2GPI) antibodies
ID2 and IIC5 induced a TLR4/myeloid differentiation
primary-response gene 88 (MyD88)-mediated pro-
inflammatory response in the human first-trimester
trophoblast line HTR-8, leading to reduced cell viabil-
ity and up-regulation of interleukin (IL)-8, monocyte
chemo-attractant protein (MCP)-1, growth-related
oncogene (GRO)-a and IL-1b. They also demonstrated
that IgG purified from patients with APS and PM stim-
ulated trophoblast production of IL-8 and GRO-a12
significantly more than IgG from patients with APS
but no PM (thrombosis only). In a functional assay,
this group subsequently demonstrated that ID2 and
IIC5 also inhibit invasion of HTR-8 cells across a mem-
brane13 but did not study the effects of polyclonal IgG
from patients with APS in that assay.
In this study, we report a comparison of the effects
of IgG from patients with VT+/PM, patients with
VT/PM+ and healthy control (HC) subjects on
invasion of human trophoblast cells and their intra-
cellular effects on the TLR4 pathway. TLR signalling
is mediated via a family of five adaptor proteins:
MyD88, MyD88-adaptor-like (MAL), toll/interleu-
kin-1 receptor-domain-containing adaptor protein
inducing interferon-b (TRIF), TRIF-related adaptor
molecule (TRAM) and sterile a- and armadillo-
motif-containing protein (SARM).14 Stimulation of
TLR4 facilitates the activation of two pathways: the
MyD88-dependent or MyD88-independent pathway
with recruitment of TRIF and TRAM. The activation
of the TLR4 MyD88-dependent pathway leads to
activation of p38 MAPK and/or NFjB. Therefore, in
this study, we looked at expression of TLR4, MyD88,
TRIF and phosphorylation of p38 MAPK, NFjB and
extracellular signal-regulated kinase (ERK). We also
measured levels of the cytokines IL-8 and IL-6 as
they are all important in regulating trophoblast
growth and function. Furthermore, their expression
has been shown to be increased when HTR-8 cells
are exposed to human or murine aPL.12,13
Materials and methods
Patients
Serum samples from 22 individuals were obtained for
this research from patients under our care at University
College London Hospital, London, UK, and through
Professor Silvia Pierangeli at University of Texas Medi-
cal Branch, Galveston, USA, and Professor Pier Luigi
Meroni at University of Milan, Milan, Italy. All the
subjects signed consent forms approved by the local
ethics committees at each institution. Of 16 patients
fulfilling the classification criteria for APS,15 nine had a
history of VT alone (VT+/PM) and seven had experi-
enced only PM (VT/PM+). Serum samples from six
aPL-negative healthy controls (HC) were also used.
Purification and Immunological Characterization of
IgG
All polyclonal IgG was purified by protein
G–Sepharose chromatography (Pierce, UK), passed
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through Detoxi-GelTM Endotoxin removing columns
(Pierce, UK) and subsequently determined to be
endotoxin free (<0.125 Endotoxin units/mL) by the
Limulus amebocyte lysate assay (Sigma, Gillingham,
UK). The polyclonal APS-IgG was purified from
stored serum samples that were confirmed to have
aCL and anti-b2GPI activity. The aCL and anti-
b2GPI activity of IgG was then measured as
described previously16 using international calibra-
tors in G phospholipid units (GPLU, from APL
Diagnostics, Galveston, TX, USA) for the CL assay
and an in-house standard of a patient with positive
aPL (but no APS) with known anti-b2GPI binding
for the anti-b2GPI assay [results expressed as stan-
dard units (SU)]. Pooled IgG was obtained by com-
bining an equal concentration of IgG with similar
aPL binding from five individual samples in the
VT+/PM, VT/PM+ and HC groups shown in
Table I. Two different batches, each consisting of
overlapping IgG from the three comparator groups,
of pooled IgG were used in these experiments.
First-trimester Trophoblast Cell Line
The human first-trimester extravillous trophoblast
cell line HTR-8, immortalised by SV40,17 was kindly
provided by Dr Charles Graham from Queen’s Uni-
versity, Kingston, Ontario, Canada. HTR-8 cells were
cultured in RPMI 1640 (Gibco), supplemented with
10% foetal bovine serum (PAA Laboratories, GE
Healthcare Life Sciences, Bucks, UK) and 100 units/
mL penicillin 100 lg/mL streptomycin (Gibco,
Paisley, UK) and maintained at 37°C/5% CO2. Cells
were treated with 100 lg/mL of a pool of either
VT+/PM IgG, VT/PM+ IgG or HC-IgG. Each IgG
pool was derived from five individual patients or
controls. In some instances, HTR-8 cells were
pre-treated for 1 hr with 1 lM of the TLR4 inhibitor
CLI-095 (InvivoGen, Toulouse, France), which
blocks the signalling mediated by the intracellular
domain of TLR4 or 1 lg/mL of Ultra Pure Rhodobact-
er sphaeroides LPS (InvivoGen), a TLR4 antagonist
that does not induce TLR4 signalling.
Trophoblast Cell Invasion Assay
The QCM 24-well collagen-based cell invasion assay
(Chemicon International, Temecula, CA, USA) was
used to compare the ability of HTR-8 cells incubated
with APS-IgG or HC-IgG to invade through a colla-
gen layer. In short, invasion chamber inserts con-
taining a collagen layer above a polycarbonate
membrane were placed into wells of a 24-well tissue
culture (TC) plate. 1.25 9 105 HTR-8 cells in a total
Table I Clinical and Laboratory Features of Patients and Controls
VT+/PM (n = 9) VT/PM+ (n = 7) HC (n = 6)
Age (mean  SEM) 53.3  5.9 43.4  1.9 33.5  3.7
Sex 6 F/3 M 7 F 6 F
PAPS 6 (66.6%) 6 (85.7%) 0
SLE 3 (33.3%) 1 (14.3%) 0
No. pregnancies 4 24 3
Live births 4 16 3
Total APS-related PM 0 7 (6 ST-PL, 1 TT-PL) 0
Arterial thrombosis 5 (3 CVA, 2 TIA) 0 0
Venous thrombosis 5 (4 DVT, 4 PE) 0 0
Plasma LA positive 8 6 NT
Serum aCL (mean GPLU  SEM) 144.3  23.4 120.9  14.6 4.3  0.8
Serum anti-b2GPI (mean SU  SEM) 83.3  17.3 84.4  28.9 0.2  0.1
IgG aCL (mean GPLU  SEM) 86.5  19.7 65  10.6 0  0
IgG anti-b2GPI (mean SU  SEM) 61.3  26.3 71.8  38 0  0
aCL, anti-cardiolipin antibodies; anti-b2GPI, anti-b2-glycoprotein I antibodies; CVA, cerebrovascular accident; DVT, deep vein thrombosis; F,
female; GPLU, IgG phospholipid units; LA, lupus anticoagulant; M, male; NT, not tested; PAPS, primary antiphospholipid syndrome; PM, preg-
nancy morbidity; PE, pulmonary embolus; CVA, cerebrovascular accident; SEM, standard error of the mean; SLE, systemic lupus erythemato-
sus; ST-PL, second-trimester pregnancy loss; SU, standard units; TIA, transient ischaemic attack; TT-PL, third-trimester pregnancy loss.
Lupus anticoagulant activity was checked on plasma samples by dilute Russell viper venom time and activated partial thromboplastin time.
Purified IgG was tested at the final experimental concentration of 100 lg/mL.
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volume of 300 lL were added to each invasion assay
insert and 500 lL of RPMI were added to the well of
the TC plate outside the insert. Pooled APS-IgG or
HC-IgG (100 lg/mL) was added to separate invasion
chamber inserts. Following 48 hr incubation (a time
point selected based on previous similar studies13),
each invasion chamber insert was removed from its
TC well and the non-invading cells/media from the
top of the insert were removed. The cells that had
invaded through the collagen layer to attach to the
polycarbonate membrane were collected and stained
with a dye. The amount of dye retained is a measure
of the number of cells that invaded through the col-
lagen layer and was assayed by transferring samples
to 96-well plate and reading optical density on a
TECAN GENios Microplate Reader at 560 nm. The
percentage of cells that invaded when cells were
incubated with APS-IgG were calculated relative to
an invasion control where HC-IgG was added which
was considered to have 100% invasion.
qRT-PCR
Following 6 hr incubation with 100 lg/mL pooled
APS-IgG or HC-IgG, total RNA was isolated from
HTR-8 cells using phenol–chloroform extraction. The
expression of TLR4, TRIF, MyD88, IL-8 and IL-6
mRNA was measured by qRT-PCR using TaqMan
probes (Applied Biosystems, Paisley, UK). Samples
were run on a DNA Engine Opticon continuous flu-
orescence detector (MJ Research) under the follow-
ing conditions: initial denaturation: 95°C for
10 min, followed by 41 cycles of: 95°C for 15 s,
60°C for 1 min. Gene expression was determined
relative to the housekeeping glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) gene mRNA using
the comparative cycle threshold (Ct) method. Results
are expressed as fold change relative to untreated
cells.
Immunoblot
Following 15 min incubation of HTR-8 cells with
pooled APS-IgG or HC-IgG (100 lg/mL), cell extracts
were prepared by addition of 100 lL lysis buffer
[50 mM Tris–HCl pH 7.4, 150 mM NaCl, 5 mM EDTA,
1 mM EGTA, 1% NP-40, 0.1% SDS, 0.5% NA-Deoxy-
cholate, 10 mM NaF, 1 mM Na3VO4, and complete
mini protease inhibitor cocktail tablet; Roche,
Welwyn Garden City, UK]. Cell lysate (20 lg)
was resolved on a 10% sodium dodecyl sulphate
polyacrylamide gel electrophoresis under reducing
conditions, transferred to nitrocellulose membranes,
blocked with 5% BSA and incubated overnight at 4°C
with primary antibody – rabbit anti-human phosphor-
ylated p38 MAPK (Thr180/Tyr182), total p38 MAPK,
phosphorylated NFjB p65 (Ser536), total NFjB p65,
phosphorylated p44/42 MAPK (Thr202/Tyr204) or total
ERK1 (Cell Signalling, Danvers, MA, USA) – followed
by 1-hr incubation in 1:2000 dilution of horseradish
peroxidase-conjugated goat anti-rabbit IgG (Dako,
Ely, UK). Phosphorylated and total protein for the
same signalling protein were analysed on the same
membrane. After detection of the phosphorylated pro-
tein, the antiphosphorylated protein antibody was
removed by 0.2 M sodium hydroxide and blocked
with 5% BSA. After removal of the antibody specific
for phosphorylated protein, membranes were
incubated overnight with antibody to the total protein
and the process was repeated. Protein bands were
visualized by chemiluminescence (GE Healthcare,
Amersham, UK) and their intensity quantified by den-
sitometric analysis (QuantityOne software; Biorad,
Hemel Hempstead, UK), and results were expressed as
a ratio of relative expression.
Cytokine ELISA
HTR-8 cells were incubated with pooled APS-IgG or
HC-IgG (100 lg/mL) for a range of time periods
from 2 to 72 hr. The cell culture supernatant was
collected by centrifugation at 400 g for 10 min and
stored at 80°C. IL-8 and IL-6 were measured using
commercially available ELISA kits (IL-8 BD Bio-
sciences, Oxford, UK and IL-6 R&D systems, Abing-
don, Ox, UK). Assays were performed following the
manufactures instructions. Detection and analysis
were performed using the TECAN GENios Microplate
Reader (Reading, UK).
Statistics
For each outcome, the experiments were repeated at
least three times independently and data are
expressed as mean  the standard error of the mean
(SEM) of these triplicates. Statistical analysis was
undertaken using one-way analysis of variance
(ANOVA) –Kruskal–Wallis test –with Dunsmultiple post
hoc comparison and assessed for overall statistical
significance at the 5% level (P < 0.05). Data analysis
was performed using the GraphPad Prism software
program (GraphPad Software, San Diego, CA, USA).
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Results
Clinical and Laboratory Characteristics of Subjects
The clinical and laboratory characteristics of the 16
patients with APS (9 VT+/PM and 7 VT/PM+) and
6 HC subjects are outlined in Table I. Nineteen
(86.4%) of the 22 subjects in this study were
women. Of the 16 patients with APS (both VT+/PM
and VT/PM+) four patients have SLE/APS and 12
have primary APS. Of the patients with VT+/PM,
four had venous thrombosis, four arterial thrombosis
and one patient experienced both arterial and venous
thrombosis. Of the patients with VT/PM+, six had
experienced a second-trimester foetal loss and 1 a
third-trimester foetal loss, all fulfilling APS PM classi-
fication criteria.15 Both serum and purified IgG from
patients with APS had significantly higher aCL and
anti-b2GPI activity compared to HC. The comparable
levels of individual purified IgG aCL and IgG anti-
b2GPI (tested at the final experimental concentration
of 100 lg/mL) in the VT+/PM (86.5 GPLU and 61.3
SU respectively) and VT/PM+ (65 GPLU and 71.8
SU respectively) groups indicate that any differences
in the functional effects of IgG from these two groups
are unlikely to be due to differences in levels of aPL.
The levels of aCL and anti-b2GPI activity in each pool
are shown in the relevant figure legend.
IgG Purified from Patients with Obstetric APS
Inhibit Trophoblast Invasion in a TLR4-Dependent
Manner
A significant (P < 0.05) reduction was observed in
the invasion of HTR-8 cells exposed to VT/PM+
IgG compared to HTR-8 exposed to VT+/PM IgG
and HC-IgG (Fig. 1a). This inhibition was shown to
be TLR4 dependent (Fig. 1b) as it was reversed by
pre-treatment of HTR-8 cells with the TLR4 inhibitor
CLI-095 or TLR4 antagonist Ultra Pure Rhodobacter
sphaeroides LPS restored the invasion of cells treated
with VT/PM+ IgG although only the effect of CLI-
095 reached statistical significance (P < 0.05).
IgG Purified from Patients with Obstetric APS
Induce HTR-8 Cell mRNA Expression of TLR4 and
TRIF but not MyD88 TLR Adaptor Proteins
HTR-8 cells treated with VT/PM+ IgG increased
TLR4 mRNA expression by 2.2-fold (Fig. 2a) and TRIF
mRNA expression by 3.7-fold (Fig. 2b) compared to
HTR-8 cells treated with HC-IgG, although these val-
ues were not statistically significant. VT/PM+ IgG
had no effect on MyD88 mRNA expression (Fig. 2c).
(a)
(b)
Fig. 1 IgG purified from patients with VT/PM+ APS inhibit HTR-8 cell
invasion, which is abrogated when cells are treated with a TLR4
inhibitor. The ability of HTR-8 cells to invade after treatment with
100 lg/mL pooled IgG from VT+/PM with 83.7 GPLU and 66.0SU
binding activity, VT/PM+ with 47.2GPLU and 63.8SU binding activity
and HCs with 0GPLU and SU binding (a) and following pre-treatment
with the TLR4 inhibitor CLI-095 or TLR4 antagonist, Ultra Pure
Rhodobacter sphaeroides LPS (b) was measured using a transwell
invasion assay after 48 hr. HC cell invasion was set at 100%, and the
relative invasion of HTR-8 cells exposed to APS-IgG was analysed from
this. Graph shows mean  SEM of quantitative analysis from six (a)
and three (b) independent experiments. Statistical analysis was
performed as follows: (a) one-way ANOVA (P = 0.01) with Dunn’s
multiple comparisons test (*P < 0.05); (b) one-way ANOVA (P = 0.03)
with Dunn’s multiple comparisons test (*P < 0.05).
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In contrast, VT+/PM IgG had no effect on expression
of any of these mRNAs. Fig. 2d shows that pre-treat-
ment with the TLR4 inhibitor CLI-095 abrogated the
increased TRIF mRNA expression seen in HTR-8 cells
treated with VT/PM+ IgG, although this difference
failed to reach statistical significance.
IgG Purified from Patients with APS do not
Promote the Phosphorylation of p38 MAPK, NFjB
p65 or ERK or the Production of the Cytokines IL-
8 or IL-6 in HTR-8 Cells
We then measured whether the APS-IgG-mediated
stimulation of TLR4 led to preferential phosphoryla-
tion of MyD88-dependent (p38 MAPK, NFjB p65 or
ERK) pathways in HTR-8 cells. Fig. 3a–c shows that
neither VT+/PM IgG nor VT/PM+ IgG increase
the phosphorylation of p38 MAPK, NFjB p65 or
ERK in HTR-8 cells compared to that seen in
untreated cells.
We also investigated HTR-8 cell expression of IL-8
and IL-6, following incubation with APS-IgG and
HC-IgG utilising both qRT-PCR and ELISA. There
was no difference in the mRNA or protein expres-
sion of any of these cytokines in HTR-8 cells treated
with VT+/PM IgG, VT/PM+ IgG or HC-IgG at any
time point from 2 to 72 hr. Fig. 4a–d shows the
results for mRNA at 6 hr and protein expression at
72 hr (the time points where mRNA and protein
expression respectively were maximal in cells
exposed to TNF-a, the positive control).
Discussion
This study has shown that only IgG from patients
with obstetric (non-thrombotic) APS inhibit tropho-
blast invasion in-vitro in a TLR4-dependent manner,
compared with thrombotic APS-IgG which lacked
this effect. Furthermore, only obstetric APS-IgG
increased the transcript expression of TLR4 and TRIF,
(a) (b) (c)
(d)
Fig. 2 HTR-8 cells treated with VT/PM+ IgG but not HTR-8 cells treated with VT+/PM IgG increase TLR4 and TRIF transcript levels. HTR-8
cells were treated with 100 lg/mL pooled IgG from VT+/PM with 78.2GPLU and 44.4SU binding activity, VT/PM+ with 83.4GPLU and
71.5SU binding activity and HCs with 0GPLU and SU binding. TLR4 (a), TRIF (b) and MyD88 (c) mRNA expression at 6 hr was measured by
qRT-PCR. TRIF mRNA expression in HTR-8 cells pre-treatment with the TLR4 inhibitor CLI-095 before treatment with 100 lg/mL pooled IgG
from VT+/PM, VT/PM+ and HCs was also measured (d). The mean  SEM of quantitative analysis from four independent experiments is
shown. Results are expressed as fold change of either TLR4, TRIF or MyD88/GAPDH, relative to untreated cells. No statistically significant
differences were found by one-way ANOVA.
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although this difference failed to reach statistical sig-
nificance. However, neither VT+/PM nor VT/PM+
IgG had any effect on MyD88 mRNA expression,
phosphorylation of the p38 MAPK, NFjB or ERK
signalling pathways or expression of IL-8 and IL-6 in
this experiment.
These results can be compared with our previous
work on human monocytes.11 In those cells, we
found the reverse, that is, that only thrombotic (VT+/
PM) IgG had a functionally important effect (of
increased TF activity), whereas VT/PM+ IgG had no
effect. Although that effect on monocyte TF activity
was also reduced by TLR4 inhibition, it seems likely to
have been mediated via different signalling pathways
to those involved in the HTR-8 cells because we
observed increased phosphorylation of the p38 MAPK
and NFjB signalling pathways in monocytes treated
with VT+/PM IgG. Currently, the mechanism of the
TLR4-dependent effect on HTR-8 cells demonstrated
in our experiment is unclear.
The inhibitory effects of APS-IgG upon the inva-
sion of trophoblast cells in-vitro are well-docu-
mented.13,18–20 The mechanisms underlying these
inhibitory effects are likely to be complex and are
not fully understood. In an important series of
papers, Mulla and colleagues used the murine
monoclonal anti-b2GPI antibodies ID2 and IIC5 to
demonstrate both TLR4-dependent and TLR4-inde-
pendent effects on human trophoblast cells. Thus, in
HTR-8 cells, these antibodies cause TLR4-dependent
up-regulation of the inflammatory cytokines IL-8,
MCP-1, GRO-a and IL-1b12 but TLR4-independent
reduction of IL-6 secretion and signal transducer and
activator of transcription (STAT)-3 activation.13 They
also showed that these monoclonal antibodies inhibit
HTR-8 invasion but did not investigate whether that
effect was TLR4-dependent (although it was IL-6-
dependent). ID2 and IIC5 also cause TLR4-indepen-
dent but MyD88-dependent secretion of angiogenic
factors, which is not reversed by heparin.21 Most
recently, this group showed that these two murine
monoclonal antibodies stimulate production of uric
acid in a different trophoblast line (Sw.71) in a
TLR4-dependent manner, which activates the in-
flammasome and promotes IL-1b processing and
secretion.22
Comparing our results using polyclonal human
anti-b2GPI antibodies with those of Mulla et al. using
(a) (b)
(c)
Untreated TNF-α VT+/PM- VT-/PM+ HC Untreated TNF-α VT+/PM- VT-/PM+ HC
p-p38
p38





Fig. 3 APS-IgG do not increase the
phosphorylation of p38 MAPK, NFjB p65 or
ERK. HTR-8 cells were treated with 100 lg/mL
pooled IgG from VT+/PM with 78.2GPLU
and 44.4SU binding activity, VT/PM+ with
83.4GPLU and 71.5SU binding activity and
HCs with 0GPLU and SU binding as well as
the positive controls TNF-a (10 ng/mL).
Graphs show relative expression at 15 min of
p38 MAPK (a), NFjB p65 (b) and ERK (c). The
mean  SEM of quantitative analysis from
three independent experiments is shown. No
statistically significant differences were found
by one-way ANOVA.
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xenogenic anti-b2GPI monoclonals, we have observed
many complementary findings. We have demon-
strated a TLR4-dependent mechanism of inhibition of
HTR-8 invasion by human APS-IgG, which may oper-
ate in addition to the TLR4-independent, IL-6-depen-
dent inhibition described by Mulla’s group. As we did
not use dominant-negative MyD88 transfection vec-
tors, we cannot be sure whether this inhibition acts
via MyD88. Given our findings, however, we suspect
that it is more likely to operate via the TRIF/TRAM
pathway, although we were unable to optimise exper-
iments to confirm increased TRIF expression at the
protein level. Previous work examining the involve-
ment of TLR adaptor proteins in APS-mediated cell
signalling in other non-obstetric cell types focussed
upon the MyD88 pathway. Human anti-b2GPI anti-
bodies have been shown to activate endothelial cells
in a MyD88-dependent manner through involvement
of TLRs.23 Studies of the human monocytic THP-1 cell
line have shown that incubation with rabbit anti-
b2GPI/b2GPI complexes increased TF mRNA expres-
sion, TF activity, and expression of TLR4, MyD88, and
myeloid differentiation protein-2, a critical cofactor
that interacts with TLR4.24 Recently, the same group
showed that treatment of healthy ex vivo monocytes
or THP-1 cells with monoclonal anti-b2GPI/b2GPI
complexes increased MyD88 and TRIF mRNA and
protein expression and this effect was blocked by
addition of TAK-242, a blocker of signalling transduc-
tion mediated by the intracellular domain of TLR4.25
To our knowledge, we are the first to identify the
involvement of TRIF in APS TLR4-mediated tropho-
blast signalling.
It is difficult, however, to make a direct compari-
son between experiments using xenogenic monoclo-
nal and spontaneous autoimmune anti-b2GPI
antibodies, because obvious differences exist such as
epitope specificity and avidity. The strongest evi-
dence for pathogenicity relates to antibodies against
b2GPI, which has five domains (DI-DV), particularly
those antibodies directed against DI. We26 and other
groups27–31 have shown that circulating levels of IgG
aDI are elevated in patients with APS in comparison
with healthy and disease controls. The xenogenic
anti-b2GPI monoclonals described above have been
shown to recognise epitopes in DV32 whilst 7 of 16
APS-IgG used in our study bind DI. The clinical asso-
ciation and titre of anti-DI binding of serum samples
in this study are shown in Table S1. Four of the
VT+/PM and three of the VT/PM+ samples are
aDI positive. None of the samples were tested for
binding to other domains of b2GPI, as their signifi-
cance is yet to be established in APS, and they are
not currently being developed as non-criteria assays
for clinical use in APS.33
A potential disadvantage, however, of using poly-
clonal compared with monoclonal IgG is that the
observed biological effect may attributed to another
autoantibody population such as may be found in
patients with SLE. We do not believe, however, that
(a) (b)
(c) (d)
Fig. 4 APS-IgG do not increase the transcript
or protein secretion of the cytokines IL-8 and
IL-6 in HTR-8 cells. HTR-8 cells were treated
with 100 lg/mL pooled IgG from VT+/PM
with 83.7 GPLU and 66.0SU binding activity,
VT/PM+ with 47.2GPLU and 63.8SU binding
activity and HCs with 0GPLU and SU binding
as well as the positive controls TNF-a (10 ng/
mL). Graphs (a–d) show qRT-PCR analysis of
IL-8 (a), and IL-6 (c) mRNA expression at 6 hr
and ELISA results of IL-8 (b) and IL-6 (d)
protein expression at 72 hr. The
mean  SEM of quantitative analysis from
four independent experiments is shown. No
statistically significant differences were found
by one-way ANOVA.
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the inclusion of SLE/APS in our pooled samples has
adversely affected our results for several reasons.
First, the clinical and serological features of APS and
SLE associated APS are known to be similar.1,34 Sec-
ond, we have previously shown that whereas IgG
from patients with APS (with or without SLE) stim-
ulated phosphorylation of NFkB or p38MAPK and
increased TF activity in human monocytes compared
with healthy control IgG, purified IgG from aPL-
positive patients with SLE but no APS (APL+/APS)
did not stimulate any of these effects in monocytes.
This lack of effect was seen despite the fact that nine
of 12 patients from this aPL+/APS group had a
range of other serum autoantibodies, such as anti-
dsDNA and anti-Ro.11 These differences between
monoclonal and polyclonal IgG may partly explain
why, in contrast to previous papers, we did not
demonstrate effects of APS-IgG on secretion of the
cytokines IL-8 or IL-6 in HTR-8 cells. Notably, the
absolute levels of IL-6 (both mRNA and protein) in
cells exposed to APS-IgG in our experiment were
similar to those described by Mulla et al.12,13 The
difference in our experiment was the inclusion of
cells exposed to HC-IgG and as these cells also
secreted IL-8 or IL-6 at similar levels we were
unable to confirm a specific effect of the APS-IgG
samples on these outcomes.
Trophoblast invasion and successful implantation
in vivo depend on a complex series of molecular and
cellular events that are induced in the pregnant
uterus by various paracrine and autocrine regulators
in addition to cytokine release.35 Therefore, future
experiments will require measurement of these fac-
tors in response to IgG purified from patients with
only thrombotic or obstetric APS in both in vitro and
in vivo models. In particular, LPS-mediated stimula-
tion of macrophages undergoing endoplasmic reticu-
lum stress has recently been shown to produce
mature IL-1b via TLR4, caspase-8 and TRIF-depen-
dent signalling pathways.36 Therefore, it will be
important to address the potential involvement of
caspase 8 and other APS-IgG-mediated signalling in
HTR8 and primary trophoblast cells.
We used two different batches of pooled IgG cre-
ated from five individuals for the APS-IgG and HC-
IgG preparations. Our use of pooled samples enabled
us to test the different comparison groups against a
large number of biological outcomes on trophoblast
cells which would not have been possible if we had
tested multiple samples from each of the studied
groups. In creating these different batches of pooled
IgG for our experiments, it proved impossible to pro-
duce a second batch of all-female IgG with similar
aPL binding between aPL subgroups. Therefore, it
was necessary to include three male samples. Inter-
estingly, monoclonal IgG aCL from male patients has
been shown to induce foetal loss in naive mice as
well as the IgG from female patients with obstetric
APS.37 Therefore, we do not believe that inclusion of
these male samples has adversely affected our find-
ings, although future experiments will include an
all-female cohort.
Similarly, we were unable to match our compara-
tor groups for parity. Interestingly, many previous,
similar studies of the effects of aPL upon trophoblast
cells have not matched parity between test and con-
trol groups. For instance, Mulla et al.12 and Carroll
et al.21 examined the same cohort of (n = 6) VT+/
PM patients with three live births from six preg-
nancies and (n = 6) VT/PM+ patients with six live
births from 22 pregnancies; Bose et al.19 examined
(n = 3) LA-positive patients with recurrent miscar-
riage with a mean number of live births of 0.3
(range 0–1) from a mean number of first-trimester
miscarriages was 4.2 (range 3–8) and (n = 3) control
human sera with an undisclosed number of preg-
nancies; Jovanovic et al.20 examined (n = 13)
patients with APS and (n = 10) control human sera
with an undisclosed number of pregnancies; and
Mulla et al.22 examined (n = 55) aPL+ patients with
10 of 55 adverse pregnancy outcomes compared
with (n = 113) healthy controls of whom four had
an adverse pregnancy outcome. In contrast, di Si-
mone et al.18 were able to match parity in their
examination of (n = 2) APS samples with no live
births from five pregnancies and (n = 2) aPL+/APS
samples with four live births from four pregnancies.
In our cohort, we have found that women in the
VT+/PM group are less likely to want to become
pregnant because they are on warfarin and also have
an appreciable risk of DVT in pregnancy, so it is
intrinsically difficult to match parity in these groups.
This finding of reduced parity in patients with SLE is
well known and one study of (n = 119) women with
SLE found that they viewed their disease as a barrier
to childbearing38 and another multicentre study
found that 42% of (n = 339) women with SLE diag-
nosed before 50 years of age had never been preg-
nant.39 Overall, we do not believe that the lack of
parity between groups in our and other similar stud-
ies will have had a significant influence upon our
findings.
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None of the samples available to us at the time
of testing were derived from patients with recurrent
first-trimester miscarriage fulfilling APS criteria;
thus, we were unable to compare effects of IgG
from patients with early and late APS-related preg-
nancy loss. In fact, two patients with VT/PM+ had
experienced a single first-trimester miscarriage,
although we cannot be certain that these events
were APS-related so have not included this clinical
information in Table I. Interestingly, the recent
obstetric APS taskforce identified that although a
majority of studies report a positive association
between aPL and recurrent early miscarriage these
studies are highly heterogenous regarding clinical
events and laboratory criteria, so very few actually
meet APS classification criteria.40 This taskforce also
noted heterogeneity in studies of late pregnancy
manifestations but found a stronger association
between late pregnancy morbidity (foetal death,
pre-eclampsia, IUGR) and aPL from more recent
multicentre prospective studies and an association
with double/triple aPL positivity and higher titres of
aPL. Therefore, selection of samples with late preg-
nancy APS manifestations may actually be advanta-
geous as this aPL profile is most likely to have
comparable aPL titres with thrombotic APS samples
which usually display the highest titres as was the
case in our cohort. In future work, however, it will
be important and to select VT/PM+ patients with
recurrent first-trimester miscarriage, to confirm that
they have a similar effect upon trophoblast cells to
the samples with late pregnancy morbidity that we
studied.
In classifying our patients with VT+/PM or VT/
PM+, we cannot completely exclude the possibility
that a patient who has previously suffered only VT
may subsequently develop PM or vice versa. Patients
in the VT/PM+ group, however, with a mean age of
43.1 years have been followed up for many years
with no VT event (>10 years for all UCLH patients).
Of the six women in the VT+/PM group, four had
never been pregnant (for reasons of personal choice).
The other two had two normal pregnancies each.
Therefore, although some of the patients with VT+/
PM could theoretically be misclassified (as they
could have had PM if they had ever been pregnant),
such misclassification of patients would have reduced
our chance of being able to distinguish a difference
between groups rather than leading to false-positive
differences. In future experiments, it would be impor-
tant to repeat this work using samples from individual
patients and to study the effects of these different
groups of IgG upon maternal/decidual cells.
In summary, we have identified that IgG isolated
from patients with APS-related PM preferentially
inhibit the invasion of a human trophoblast cell line
compared with APS-IgG from patients with VT alone.
This effect is dependent on TLR4. Further experiments
are now required to characterize the mechanistic and
prognostic implications of these findings.
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